Diagnostic Characteristics and Problems

1981 ◽  
pp. 97-117
Author(s):  
H. Robinson
Keyword(s):  
Diagnostic Characteristics

scholarly journals Diagnostic characteristics of 11 formulae for calculating corrected flow time as measured by a wearable Doppler patch

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Jon-Émile S. Kenny ◽  
Igor Barjaktarevic ◽  
David C. Mackenzie ◽  
Andrew M. Eibl ◽  
Matthew Parrotta ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Sensitivity And Specificity ◽  
Doppler Ultrasound ◽  
Flow Time ◽  
Cardiac Preload ◽  
Respiratory Cycle ◽  
Quiet Breathing ◽  
Diagnostic Characteristics ◽  
Corrected Flow Time ◽  
Corrected Flow

Abstract Background Change of the corrected flow time (Ftc) is a surrogate for tracking stroke volume (SV) in the intensive care unit. Multiple Ftc equations have been proposed; many have not had their diagnostic characteristics for detecting SV change reported. Further, little is known about the inherent Ftc variability induced by the respiratory cycle. Materials and methods Using a wearable Doppler ultrasound patch, we studied the clinical performance of 11 Ftc equations to detect a 10% change in SV measured by non-invasive pulse contour analysis; 26 healthy volunteers performed a standardized cardiac preload modifying maneuver. Results One hundred changes in cardiac preload and 3890 carotid beats were analyzed. Most of the 11 Ftc equations studied had similar diagnostic attributes. Wodeys’ and Chambers’ formulae had identical results; a 2% change in Ftc detected a 10% change in SV with a sensitivity and specificity of 96% and 93%, respectively. Similarly, a 3% change in Ftc calculated by Bazett’s formula displayed a sensitivity and specificity of 91% and 93%. FtcWodey had 100% concordance and an R2 of 0.75 with change in SV; these values were 99%, 0.76 and 98%, 0.71 for FtcChambers and FtcBazetts, respectively. As an exploratory analysis, we studied 3335 carotid beats for the dispersion of Ftc during quiet breathing using the equations of Wodey and Bazett. The coefficient of variation of Ftc during quiet breathing for these formulae were 0.06 and 0.07, respectively. Conclusions Most of the 11 different equations used to calculate carotid artery Ftc from a wearable Doppler ultrasound patch had similar thresholds and abilities to detect SV change in healthy volunteers. Variation in Ftc induced by the respiratory cycle is important; measuring a clinically significant change in Ftc with statistical confidence requires a large sample of beats.

scholarly journals The PCL Envelope Lack Sign (PELS) Is a Direct Arthroscopic Sign of Chronic Posterior Cruciate Ligament Insufficiency

2021 ◽  
Vol 11 (8) ◽  
pp. 3608
Author(s):  
Adrian Góralczyk ◽  
Marcin Mostowy ◽  
Michał Ebisz ◽  
Robert F. LaPrade ◽  
Aleksandra Sibilska ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Predictive Value ◽  
Femoral Condyle ◽  
Cruciate Ligament ◽  
Normal Space ◽  
Control Group ◽  
Study Group ◽  
Post Injury ◽  
Diagnostic Characteristics ◽  
Posterior Knee

Purpose: To present the arthroscopic “PCL envelope lack sign” (PELS) and to calculate its diagnostic characteristics in chronic PCL insufficiency. Methods: Recordings of knee arthroscopies performed in a single clinic between April 2015 to March 2020 were retrospectively evaluated, searching for the “PCL envelope”. It was defined as a “soft tissue cuff coursing around the PCL tibial attachment, visible with the arthroscope positioned between the PCL, medial femoral condyle and posterior horn of the medial meniscus at the level of its shiny white fibers”. PELS was defined as “the PCL adhering to the proximal tibia adjacent to the medial meniscal posterior root attachment, inability to observe the normal space between the PCL and posterior tibia and no soft tissue cuff around the PCL tibial attachment”. Inclusion criteria were possibility to evaluate the PELS presence on recordings. Patients who underwent PCL reconstruction were assigned to the study group. The rest of the patients were controls. Criteria to operate on symptomatic PCL patients were at least 5 mm of posterior instability in physical examination and at least 6 months post-injury. Results: Out of 614 available recordings, 592 patients (205 females, 387 males; mean age 45.2 years, SD = 14.36, range 14–81) were included: 38 in the study group and 554 in the control group. In the study group, PELS was positive in 36 of 38 cases (94.7%). In the control group, PELS was negative in 554 PCL-efficient patients (100%). Calculated PELS sensitivity was 94.7%, specificity 100%, positive predictive value 100%, negative predictive value 99.6%. The PELS was present significantly more often in PCL-insufficient patients, p < 0.001. Conclusions: The PCL envelope lack sign was found to be a highly effective tool to arthroscopically confirm chronic PCL insufficiency, and should be considered a direct sign of chronic posterior knee instability.

Improving on the diagnostic characteristics of echocardiography for pulmonary hypertension

2017 ◽  
Vol 33 (9) ◽  
pp. 1341-1349 ◽  
Author(s):  
Kathleen Broderick-Forsgren ◽  
Clemontina A. Davenport ◽  
Joseph A. Sivak ◽  
Charles William Hargett ◽  
Michael C. Foster ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Diagnostic Characteristics

Mental health care utilization among veterans with castration-resistant prostate cancer receiving abiraterone or enzalutamide.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18680-e18680
Author(s):  
Phoebe A. Tsao ◽  
Jennifer A. Burns ◽  
Shami Entenman ◽  
Kyle Kumbier ◽  
Jordan Sparks ◽  
...  
Keyword(s):  
Mental Health ◽  
Prostate Cancer ◽  
Health Care ◽  
Mental Health Care ◽  
Health Administration ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Castration Resistant ◽  
Diagnostic Characteristics ◽  
Comorbidity Burden

e18680 Background: Abiraterone and enzalutamide are oral therapies widely used to treat men with castration-resistant prostate cancer (CRPC). Recent data have suggested potentially worsened quality of life and depression with use of enzalutamide compared to abiraterone. Because Veterans are at a higher risk for mental health conditions, we sought to compare mental health service utilization in Veterans with CRPC receiving enzalutamide to those receiving abiraterone. Methods: The Veterans Health Administration Corporate Data Warehouse was used to identify men with CRPC who received abiraterone or enzalutamide for ≥ 30 days as first-line treatment between 2010-2017. We compared the rate of mental health visits per 100 patient-months for men on abiraterone versus enzalutamide using an exact rate ratio test, assuming Poisson counts. Results: Among 2902 male Veterans, 68.6% (n=1992) received abiraterone and 31.4% (n=910) enzalutamide as first-line therapy. Men who received enzalutamide were older (76 vs 74, p<0.01) and had a higher comorbidity burden (Charlson Comorbidity Index [CCI] ≥ 2 in 28.7% vs 21.6%, p<0.01); no differences were noted in race or prevalence of preexisting documented mental health diagnoses. Median time on drug was 8 months for both medications. There was no difference in the rate of mental health visits per 100 patients-months on enzalutamide versus abiraterone (6.6 v. 6.7, p=0.66). However, within patient sub-groups, men who were age 75 or older, not married, or without notable comorbidities had lower rates of mental health visits with enzalutamide compared to abiraterone; whereas those who were younger than 75, married, had higher comorbidities, or a preexisting mental health diagnosis had higher rates of mental health visits with enzalutamide (Table). Conclusions: Among Veterans with CRPC who received a novel antiandrogen therapy first-line, there was no difference in engagement in mental health care between those who received abiraterone versus enzalutamide. Sub-group analysis revealed significant differences between patients on the two medications in demographic and diagnostic characteristics associated with number of visits, suggesting that vulnerability for mental health symptoms may vary by medication type. Further work in understanding the long-term impact of novel antiandrogens on mental health is needed.[Table: see text]

Ferulago akpulatii (Apiaceae): A new species from Central Anatolia, Turkey

Phytotaxa ◽  
2021 ◽  
Vol 518 (2) ◽  
pp. 100-108
Author(s):  
BAHAR GÜRDAL ◽  
BÜLENT OLCAY ◽  
HÜSEYİN ONUR TUNCAY ◽  
EMİNE AKALIN
Keyword(s):  
New Species ◽  
Leaf Shape ◽  
Identification Key ◽  
Central Anatolia ◽  
Cauline Leaf ◽  
Anatomical Features ◽  
Diagnostic Characteristics ◽  
Morphological Differences ◽  
A New Species ◽  
Inflorescence Type

Ferulago akpulatii (Apiaceae) is described as a new species endemic to Central Anatolia, Turkey. It is closely related to Ferulago platycarpa and F. pauciradiata, and is easily distinguished by its cauline leaf shape, inflorescence type, and fruit features. The main morphological differences between Ferulago akpulatii and related taxa are discussed, and the diagnostic characteristics, including the anatomical features of fruits, are given in detail. An identification key of Ferulago akpulatii and the morphologically closer species is also provided.

Sign in / Sign up

Export Citation Format

Share Document